Novel Inhibitors of Thymic Stromal Lymphopoietin (TSLP) for Cancer Therapy
Compositions and methods of using antagonists of thymic stromal lymphopoietin (TSLP) to prevent cancer progression and metastasis.
TSLP, an inflammatory cytokine that is often associated with the induction of allergic responses in the lungs, is also expressed in cancers regulating metastasis. The cancer-promoting activity of TSLP primarily requires signaling through a receptor on CD4+ T-cells, promoting immune responses and production of immunosuppressive factors such as IL-10 and IL-13. Expression of TSLP may be a useful prognostic marker and inhibitors of TSLP could have therapeutic potential. Inactivation of TSLP expression or its receptor signaling was able to effectively diminish cancer progression and metastasis in knock-out mice.
Source:
Novel Inhibitors of Thymic Stromal Lymphopoietin (TSLP) for Cancer TherapyLinkback: https://tubagbohol.mikeligalig.com/index.php?topic=65274.0
